Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Post from Dr Joey Johnson on FB ———

People have been asking me if I'm going to sell after we get Emergency Use Authorization? Of course not! Or, if I think life is over if we don't get EUA? Again - of course not! ———

Here is something for you to think about if you have considered asking me or any other Longs this question:

1. Non-Covid 19 ARDS + pulmonary sarcoidosis = more $ via peak sales est. than COVID-19 Induced ARDS ———

2. APR TD-011 is where the bigger money pot is! We'll actually make more $ from this APR drug than inhaled Aviptadil for ARDS with full approval! ———

3. Besides Aviptadil and it's various forms, the following drugs will launch this year:
a) APR TD011
b) SENTINOX
c) NEXODYN
d) ACER-001 (2021/2022) ———

I'm in the Class of 2025! In other words, I've got my eyes set on holding at least half of my shares until then! GLTA!
——>

I’m here for Aviptadil, but after seeing Dr Joey post I researched RLF owned APR & the APR treatment for EB;

EB affects ~500,000 ———

& annual treatment varies from $10k to $300k per year per patient ———

& here is what I found:

For Epidermolysis Bullosa, no approved treatments or cure are available. ———

The standard of care is currently palliative treatments for blisters and wounds all over the body for the entire life. ———

Itching, pain, and scarring strongly reduce the quality of life while persistent skin inflammation is correlated to tumor incidence and death. ———

EB imposes a major burden for global health care ———

The cost of the treatment of a severely affected patient in the United States can approach $300,000 per year, wound care supplies for those with EB are estimated more than $10,000 per month. ~ Equalizer, RLFTF @ Y@h00 finance conversations
—————->

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to APR-TD011, a spray therapy candidate for the treatment of epidermolysis bullosa (EB). ———

This designation is intended to encourage the development of therapies for rare and serious diseases, which are expected to outperform existing alternatives. ———

Among its benefits are seven years of market exclusivity, exemption from FDA application fees, the agency’s assistance in clinical trial design, and tax credits for trial expenses. ———

https://epidermolysisbullosanews.com/2019/12/18/spray-therapy-apr-td011-s-fda-orphan-drug-status-treat-eb-epidermolysis-bullosa/